海正藥業(600267.SH):聘任李琰為公司總裁
格隆匯4月19日丨 海正藥業(600267.SH)公佈,公司於2022年4月19日召開的第九屆董事會第一次會議審議通過了《關於聘任公司總裁的議案》,董事會同意聘任李琰為公司總裁,任期至本屆董事會屆滿時止。
李琰,男,1976年8月出生,碩士。歷任西格瑪奧德里奇(上海)貿易有限公司業務發展總監,卡博特(中國)投資有限公司業務發展總監,方源資本副總裁,工銀國際融通資本執行董事、董事總經理,吉林省博大製藥股份有限公司董事長、總經理。現任公司總裁、董事,兼任雅賽利(台州)製藥有限公司副董事長、晟鼎醫藥(上海)有限公司法定代表人兼執行董事、海正(海南)醫學科技發展有限公司董事兼總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.